Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.Galecto acquired Damora Therapeutics, Inc., a privately held biotechnology company advancing a pipeline of antibody therapeutics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.Myeloproliferative neoplasms are a group of rare blood cancers where the bone marrow pro ...

Core Insights - Incyte Corp has raised its annual sales forecast for Jakafi, a blood cancer treatment, due to strong demand that exceeded Wall Street estimates for the third quarter [1] Financial Performance - The company reported robust demand for Jakafi, leading to a positive financial outlook [1] - The updated sales forecast reflects confidence in the drug's market performance [1]